- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01113554
Breast Cancer Rehabilitation Program in Improving Quality of Life in Breast Cancer Survivors
A Pilot Study to Evaluate the Feasibility of a Breast Cancer Rehabilitation Program in Survivors of Breast Cancer
RATIONALE: A breast cancer rehabilitation program and exercise therapy may help improve the quality of life of breast cancer survivors.
PURPOSE: This clinical trial studies a breast cancer rehabilitation program in improving quality of life in breast cancer survivors.
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To estimate accrual, retention, adherence, and participation of breast cancer survivors to a breast cancer rehabilitation program.
II. To estimate the variability of weight, six-minute walk, quality of life and other psychosocial and physical measures in women participating in the BCRP.
SECONDARY OBJECTIVES:
I. To assess changes in the anthropometric, psychosocial, and physical outcomes over the six-month period of the BCRP.
II. To document the types and the rates of adverse events associated with the BCRP.
OUTLINE:
Patients attend exercise therapy sessions over 1 hour 3 times a week for 6 months. Exercise therapy sessions are comprised of a 10 minute warm-up of light stretching and aerobic type exercise (walking, cycling), 30 minutes of endurance type exercise (cycle, walking), and 20 minutes of resistance training exercise.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion
- First occurrence of breast cancer
- BMI >= 25
- Recently completed treatment(chemotherapy/radiation) for breast cancer (=< 8 weeks), but can be receiving adjuvant hormonal therapy
- Willing to comply with study visits, as outlined in the protocol
- Lives within 30 miles of study site, or willing to travel to study site if outside a 30-mile radius
- Ability to participate in a moderate exercise program, such as freedom from any orthopedic abnormalities that would prevent participation
- Ability to understand and the willingness to sign a written informed consent document
Exclusion
- Unstable angina
- Cardiac conduction disturbances
- Plans to move from the study area
- Dementia that is medically documented or suspected
- Advanced arterial disease causing ischemia of any limb
- Physical immobility
- Homebound for medical reasons
- Dependent on wheelchair for mobility
- Chronic disease which significantly reduces 4-year survival
- Recurrent breast cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm I
Patients attend exercise therapy sessions over 1 hour 3 times a week for 6 months.
Exercise therapy sessions are comprised of a 10 minute warm-up of light stretching and aerobic type exercise (walking, cycling), 30 minutes of endurance type exercise (cycle, walking), and 20 minutes of resistance training exercise.
|
Other Names:
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Quality of life
Time Frame: 6 months
|
6 months
|
|
BMI
Time Frame: 6 months
|
6 months
|
|
Ability to recruit breast cancer survivors into a six-month breast cancer rehabilitation program
Time Frame: Approximately 24 months
|
Approximately 24 months
|
|
Muscular strength
Time Frame: 6 months
|
6 months
|
|
Range of motion
Time Frame: 6 months
|
6 months
|
|
Proportion of screened women who are eligible for the study and the proportion of eligible women who agree to participate
Time Frame: Approximately 24 months
|
Approximately 24 months
|
|
Proportion of women who complete the study and the average number of weeks of participation
Time Frame: Approximately 24 months
|
Approximately 24 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Mara Vitolins, Wake Forest University Health Sciences
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00012783
- NCI-2010-00975
- CCCWFU 99309 (Other Identifier: Wake Forest University Health Sciences)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage I Breast Cancer
-
Mayo ClinicNational Cancer Institute (NCI)CompletedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8 | Prognostic Stage IA Breast Cancer AJCC v8 | Prognostic Stage IB Breast Cancer AJCC v8 | Prognostic Stage IIA Breast Cancer AJCC...United States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
City of Hope Medical CenterTerminatedStage I Breast Cancer | Cancer Survivor | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Ohio State University Comprehensive Cancer CenterNot yet recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Chemotherapy-Induced AlopeciaUnited States
-
Indiana University School of MedicineBreast Cancer Research FoundationCompletedQuantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer (EPC)Breast Cancer Stage IV | Breast Cancer Stage I | Breast Cancer Stage IIUnited States
-
Craig A. Bunnell, MD, MPHMassachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess... and other collaboratorsCompletedBreast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast CancerUnited States
-
Mayo ClinicNot yet recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Cancer-related Cognitive DysfunctionUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma | Early Stage HER2-Positive Breast CarcinomaUnited States
Clinical Trials on survey administration
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedSarcoma | Breast Carcinoma | Head and Neck CarcinomaUnited States
-
Boston UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingMalignant Vascular NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingMelanoma | COVID-19 InfectionUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)WithdrawnMelanoma | Breast Carcinoma | Lung Carcinoma | Colorectal Carcinoma | Community Practice | Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Institutes of Health (NIH)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
University of Rochester NCORP Research BaseNational Cancer Institute (NCI)WithdrawnCommunity Practice | StaffUnited States